Division of Cardiovascular Medicine, Department of Medicine
Biochemical Phenomena, Metabolism, and Nutrition | Cardiology | Cardiovascular Diseases | Enzymes and Coenzymes | Nutritional and Metabolic Diseases
Cardiometabolic syndrome (CMS) describes the cluster of metabolic and cardiovascular diseases that are generally characterized by impaired glucose tolerance, intra-abdominal adiposity, dyslipidemia, and hypertension. CMS currently affects more than 25% of the world's population and the rates of diseases are rapidly rising. These CMS conditions represent critical risk factors for cardiovascular diseases including atherosclerosis, heart failure, myocardial infarction, and peripheral artery disease (PAD). Therefore, it is imperative to elucidate the underlying signaling involved in disease onset and progression. The c-Jun N-terminal Kinases (JNKs) are a family of stress signaling kinases that have been recently indicated in CMS. The purpose of this review is to examine the in vivo implications of JNK as a potential therapeutic target for CMS. As the constellation of diseases associated with CMS are complex and involve multiple tissues and environmental triggers, carefully examining what is known about the JNK pathway will be important for specificity in treatment strategies.
Signaling, cardiovascular disease, metabolic regulation
Rights and Permissions
©2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
DOI of Published Version
Biosci Rep. 2019 Jul 18;39(7). pii: BSR20190267. doi: 10.1042/BSR20190267. Print 2019 Jul 31. Link to article on publisher's site
Craige, Siobhan M.; Chen, Kai; Blanton, Robert M.; Keaney, John F. Jr.; and Kant, Shashi, "JNK and cardiometabolic dysfunction" (2019). Open Access Articles. 3907.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.